MYBL2 and lung carcinoma: To investigate the therapeutic potential of B-Myb in NSCLC, we depleted the B-Myb expression via small interfering RNA (siRNA)-mediated silencing in A549 lung cancer cell lines, and cell proliferation and cell cycle assays were subsequently performed.